Delivery Order SPE2DB22D1106-SPE2DB24FDJJ3

Award Date 10/24/23
Potential Completion Date 10/25/23
Potential Value $10K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA). The award, valued at $1,721.00, is a delivery order under an Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, which has a total potential value of $999,999,999.00 and runs through November 2026. The contract is for the provision of a wide range of pharmaceutical products and...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $5,114.52 for the supply of RESTASIS 0.05% eye emulsion. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of August 10, 2021. The contract is a firm-fixed-price delivery order, and there is no set-aside designation. This award is part of a larger Indefinite Delivery Contract (IDC) valued at up to...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $7,152.41 for the supply of RESTASIS 0.05% eye emulsion. The contract was awarded by the Defense Logistics Agency (DLA) and has a completion date of September 9, 2021. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Cencora, Inc. holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $5,149.03 for the supply of RESTASIS 0.05% eye emulsion. The contract was awarded on February 28, 2022, by the Defense Logistics Agency (DLA), a defense agency of the U.S. government. The award is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025....
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $5,835.78 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product. The contract has an ultimate completion date of February 5, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to...
This federal contract award, valued at $15,990.79, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription medication, to support U.S. government healthcare programs. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999 and running through November...
This federal contract award, valued at $25,039.74, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of RESTASIS 0.05% Eye Emulsion, a prescription eye medication. This award is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 2025. The IDC serves as the primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of RESTASIS 0.05% eye emulsion. The award is a delivery order (SPE2DB23FL4M7) under an Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00, which Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Amerisourcebergen to provide a...
This federal contract award, valued at $50,773.72, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of RESTASIS 0.05% eye emulsion 60s, a specialty pharmaceutical product. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, worth up to $999,999,999.00 and running through November 2026. This IDC serves as the primary...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Restasis 0.05% eye emulsion, a specialty pharmaceutical product, with a ceiling value of $4,768.80 and a completion date of September 27, 2023. The award is part of a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through...
  • SPE2DB22D1106
    Indefinite Delivery Contract
  • SPE2DB22D1106-SPE2DB24FDJJ3
    Delivery Order

This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product, with a ceiling value of $10,033.92 and a completion date of October 25, 2023. This contract is part of a larger Indefinite Delivery Contract (IDC) that Cencora, Inc. holds with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through December 31, 2025. The IDC allows the DLA to efficiently procure a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare programs. The contract award does not have a set-aside designation, indicating open competition.

Generated 5/12/25, 10:06 AM